Q2 EPS Forecast for Gain Therapeutics Decreased by Analyst

Gain Therapeutics, Inc. (NASDAQ:GANX) – Stock analysts at Roth Capital cut their Q2 2025 earnings per share estimates for shares of Gain Therapeutics in a research report issued to clients and investors on Wednesday, May 14th. Roth Capital analyst B. Pachaiyappan now expects that the company will post earnings of ($0.18) per share for the quarter, down from their previous estimate of ($0.17). The consensus estimate for Gain Therapeutics’ current full-year earnings is ($1.00) per share. Roth Capital also issued estimates for Gain Therapeutics’ Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.19) EPS, FY2025 earnings at ($0.71) EPS, Q1 2026 earnings at ($0.20) EPS, Q2 2026 earnings at ($0.22) EPS, Q3 2026 earnings at ($0.20) EPS, Q4 2026 earnings at ($0.22) EPS and FY2026 earnings at ($0.84) EPS.

A number of other research analysts have also commented on GANX. Scotiabank started coverage on Gain Therapeutics in a research report on Friday, March 7th. They issued a “sector outperform” rating and a $12.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and issued a $8.00 price target on shares of Gain Therapeutics in a report on Monday. Finally, Chardan Capital reissued a “buy” rating and set a $6.00 price objective on shares of Gain Therapeutics in a report on Friday, March 28th. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $8.20.

Gain Therapeutics Stock Performance

Shares of Gain Therapeutics stock opened at $1.91 on Monday. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.99 and a quick ratio of 2.99. The firm has a 50 day simple moving average of $1.93 and a 200 day simple moving average of $2.00. Gain Therapeutics has a fifty-two week low of $0.89 and a fifty-two week high of $3.19. The firm has a market cap of $56.46 million, a P/E ratio of -1.74 and a beta of 0.17.

Gain Therapeutics (NASDAQ:GANX) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.16) EPS for the quarter, hitting analysts’ consensus estimates of ($0.16).

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Dauntless Investment Group LLC acquired a new position in Gain Therapeutics in the first quarter valued at about $240,000. Jones Financial Companies Lllp grew its position in shares of Gain Therapeutics by 83.6% during the 4th quarter. Jones Financial Companies Lllp now owns 98,250 shares of the company’s stock worth $212,000 after buying an additional 44,750 shares during the period. Marshall Wace LLP bought a new stake in shares of Gain Therapeutics in the 4th quarter valued at about $198,000. Northern Trust Corp raised its position in shares of Gain Therapeutics by 88.2% in the 4th quarter. Northern Trust Corp now owns 84,586 shares of the company’s stock valued at $183,000 after acquiring an additional 39,642 shares during the period. Finally, Kovitz Investment Group Partners LLC bought a new position in Gain Therapeutics during the 1st quarter worth approximately $91,000. 11.97% of the stock is currently owned by institutional investors.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.